Respiratory syncytial virus vaccine based on bacterial outer membrane vesicle
10.3760/cma.j.cn112309-20250328-00099
- VernacularTitle:基于细菌外膜囊泡的呼吸道合胞病毒疫苗的研究
- Author:
Xiaocao MENG
1
;
Yiman HUANG
;
Aijun CHEN
;
Lihong YAO
;
Chao WANG
;
Shiyuan ZHENG
;
Enrui GUAN
;
Jiayang HE
;
Lishu ZHENG
Author Information
1. 中国疾病预防控制中心病毒病预防控制所，传染病溯源预警和智能决策全国重点实验室，国家卫生健康委员会医学病毒与病毒病重点实验室，北京 102206
- Publication Type:Journal Article
- Keywords:
Respiratory syncytial virus;
Outer membrane vesicle;
Cytolysin A;
Nanovaccine
- From:
Chinese Journal of Microbiology and Immunology
2025;45(6):498-506
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the protective effect of a respiratory syncytial virus (RSV) vaccine based on bacterial outer membrane vesicle (OMV) in mice.Methods:The pre-fusion protein (preF) of RSV was linked to the surface of OMV through the transmembrane protein cytolysin A (ClyA) to form the nanovaccine OMV-preF. The morphological characteristics of OMV and OMV-preF were observed under a transmission electron microscope. OMV-preF was intramuscularly injected into BALB/c mice and the elicited humoral and cellular immune responses were evaluated. The protective effect of OMV-preF was assessed by challenging the immunized mice with RSV Long strain. One-way analysis of variance and Tukey test were used for statistical analysis.Results:The results showed that preF was stably expressed in OMV, and both OMV-preF and OMV exhibited a double-layer vesicle structures under the microscope. OMV-preF could significantly activate the cellular and humoral immune responses in mice, causing a significant increase in CD8 + T cells and CD19 + B cells as well as a significant increase in the serum level of specific IgG. The neutralizing antibodies produced in the immunized mice could significantly inhibit the replication of RSV Long strain in vivo. Conclusions:The nanovaccine OMV-preF can induce high-level humoral and cellular immune responses, and the antibodies produced following immunization can effectively inhibit viral replication. This study provides a new strategy for RSV subunit vaccines.
